FRANCE – Sanofi has been named one of the most sustainable companies in an ESG (Environment, Social, Governance) evaluation conducted by Standard & Poor’s Global Ratings (S&P).

Sanofi received an ESG Evaluation score of 86 out of 100, one of the highest scores across all sectors globally.

Sanofi’s ESG profile received 80 points for its strong fundamentals, with an additional 6 points awarded for its ‘excellent awareness of risks and opportunities’ and capacity to ‘anticipate and adapt to a variety of long-term plausible disruptions.’

Sanofi’s Social Profile was named ‘leading’ in the category of communities, highlighting the recent establishment of its global health unit in 2021, which aims to provide 30 of Sanofi’s medicines across a wide range of therapeutic areas to patients in 40 low-income countries.

Sanofi’s commitment to eliminating infectious diseases such as polio, sleeping sickness, and malaria was also mentioned in the report.

Sanofi is the first large biopharmaceutical company to be evaluated by an S&P Global Ratings ESG Evaluation, and it was particularly recognized for its commitment to medicine access, particularly in vulnerable communities.

The use of environmental, social, and governance (ESG) scores—a social credit framework for sustainability reporting, forms the primary basis for achieving the shift to a stakeholder model.

They assess both the financial and non-financial impacts of investments and businesses, and they serve to formally institutionalize corporate social responsibility in global economic infrastructure.

The creation of a nonprofit unit dedicated to providing poorest countries with access to essential medicines was identified as ‘one of Sanofi’s leading differentiators’ in the study, which recognized ‘the increasing challenges and inequalities in healthcare across all geographies.’

In the meantime, Novatek International has provided an industry-focused digital solution to Sanofi Genzyme’s Lyon, France pharmaceutical manufacturing site to improve contamination control in data integrity, automate trend analysis, and reduce workloads.

Both their environmental and utility monitoring processes were digitally transformed after a successful 12-week implementation.

The number of samples collected, protocols developed, and specifications developed was astounding, according to a case study.

The project is a success, the QC department of Sanofi Genzyme has entered the realm of digitalization of its activities!” said Yann Badinga, Project Lead at Sanofi Genzyme.

Liked this article? Sign up to receive our regular email newsletters, focused on Africa and World’s healthcare industry, directly into your inbox. SUBSCRIBE HERE